CPRX

Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CPRX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/01	05 : 50	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/06/01	05 : 47	Edgar (US Regulatory)	Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/06/01	05 : 46	Edgar (US Regulatory)	Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/06/01	05 : 43	Edgar (US Regulatory)	Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/05/31	05 : 43	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/05/31	02 : 41	GlobeNewswire Inc.	Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/05/28	21 : 03	GlobeNewswire Inc.	Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/05/22	06 : 28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/05/09	05 : 54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/05/09	05 : 16	GlobeNewswire Inc.	Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/05/09	05 : 06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/05/01	21 : 00	GlobeNewswire Inc.	Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/04/22	21 : 00	GlobeNewswire Inc.	Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/03/28	21 : 03	GlobeNewswire Inc.	Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/03/27	21 : 03	GlobeNewswire Inc.	Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/03/13	20 : 55	GlobeNewswire Inc.	Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/03/05	22 : 03	GlobeNewswire Inc.	Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/29	08 : 03	GlobeNewswire Inc.	Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/27	22 : 03	GlobeNewswire Inc.	Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/21	23 : 00	GlobeNewswire Inc.	Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/17	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/17	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/17	07 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/17	07 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/17	07 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/17	07 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/17	07 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/02/14	22 : 03	GlobeNewswire Inc.	Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/01/10	07 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc
2024/01/10	06 : 05	GlobeNewswire Inc.	Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering	NASDAQ:CPRX	Catalyst Pharmaceuticals Inc